Retiring Covidien CEO to chair Haemonetics board
This article was originally published in Clinica
Blood management specialist Haemonetics has appointed Richard Meelia chairman of its board of directors. Mr Meelia is currently CEO of Covidien but is expected to retire from this position in July (www.clinica.co.uk, 16 March 2011). He has led Covidien since 1995 and has nearly 40 years' experience in the healthcare industry. He is not new to Haemonetics, having served on the Braintree, Massachusetts firm's board between 2005-2009; he resigned to focus on his role as Covidien's CEO.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.